Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation
Authors
Keywords
-
Journal
PROSTATE
Volume 76, Issue 10, Pages 927-936
Publisher
Wiley
Online
2016-03-21
DOI
10.1002/pros.23182
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer
- (2015) R. de Leeuw et al. CLINICAL CANCER RESEARCH
- Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer
- (2015) Robert J. van Soest et al. EUROPEAN UROLOGY
- Intratumor Heterogeneity and Its Impact on Drug Distribution and Sensitivity
- (2014) I Fuso Nerini et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer
- (2014) Michael T. Schweizer et al. EUROPEAN UROLOGY
- Antiproliferative Mechanism of Action of the Novel Taxane Cabazitaxel as Compared with the Parent Compound Docetaxel in MCF7 Breast Cancer Cells
- (2014) O. Azarenko et al. MOLECULAR CANCER THERAPEUTICS
- Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone
- (2014) Daniel L. Suzman et al. PROSTATE
- Preclinical profile of cabazitaxel
- (2014) Patricia Vrignaud et al. Drug Design Development and Therapy
- Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors
- (2013) P. Vrignaud et al. CLINICAL CANCER RESEARCH
- Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography
- (2013) A. A. M. van der Veldt et al. CLINICAL CANCER RESEARCH
- Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer
- (2013) R.J. van Soest et al. EUROPEAN JOURNAL OF CANCER
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
- (2012) J. Mezynski et al. ANNALS OF ONCOLOGY
- Androgen Receptor on the Move: Boarding the Microtubule Expressway to the Nucleus
- (2012) M. Thadani-Mulero et al. CANCER RESEARCH
- Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: A practical solution for non-specific binding
- (2011) Peter de Bruijn et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Class III -Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy
- (2010) G. Ploussard et al. CANCER RESEARCH
- Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
- (2010) M.-L. Zhu et al. CANCER RESEARCH
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib
- (2009) Henk J. Broxterman et al. DRUG RESISTANCE UPDATES
- Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer
- (2008) W M van Weerden et al. BRITISH JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now